-16%

est. 2Y upside i

Series D+

Rank

#2675

Sector

Neurotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Neuralink offers a high-risk, long-duration equity bet with a negative expected 2-year return of -16%.

Last updated: July 19, 2026

Bull (20%)+80%

IPO or acquisition within 2 years driven by successful FDA approval for paralysis. Exit valuation of $18B implies 100% upside before 20% dilution, netting 80%.

Base (55%)-20%

Steady clinical progress but no liquidity event; valuation holds flat at $9B. After 20% dilution from a future round, net return is -20%.

Bear (25%)-85%

Regulatory setback or clinical failure forces a down round to $5B; common stock recovers $3.15B after $1.85B preference. Net of 20% dilution, return is -85%.

Est. time to liquidity~2.5 years

Preference Stack Risk

moderate

Funding Intensity

61%

Total funding of $1.85B represents 21% of current $9B valuation; common equity is senior only to preferred at exit.

Dilution Risk

high

With no revenue and high capital intensity, additional rounds are likely, reducing current equity by 15-25% per round.

Secondary Liquidity

limited

Secondary implied valuation of $9.7B suggests some limited secondary trades, but liquidity is not guaranteed.

Other — 71 roles

View all 71 open roles at Neuralink →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Neuralink's data — designed to show you've done your homework.

  • 1

    “How does Neuralink plan to achieve commercial reimbursement for its implants, and what is the expected timeline to revenue?”

  • 2

    “What specific clinical milestones would trigger a valuation re-rating, and how are they de-risked?”

  • 3

    “Given the high burn rate, what is your view on the likelihood of dilutive funding in 12-18 months, and how does the equity package compensate for that?”

Community

Valuation Sentiment

Our model estimates -16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.